Cerevel Therapeutics Holdings, Inc.
CERE · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $8 | $7 | $3 | $5 |
| - Cash | $0 | $1 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $8 | $7 | $4 | $5 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Gross Profit | -$0 | $0 | -$0 | -$0 |
| % Margin | – | 81.8% | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -1,556.2% | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -1,608.8% | – | – |
| EPS Diluted | -0.73 | -0.76 | -0.61 | -0.63 |
| % Growth | 3.9% | -24.6% | 3.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |